Abpro Holdings, Inc. (ABP)
NASDAQ: ABP · Real-Time Price · USD
1.530
-0.070 (-4.38%)
At close: Dec 13, 2024, 4:00 PM
1.620
+0.090 (5.88%)
After-hours: Dec 13, 2024, 5:03 PM EST
Company Description
Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues.
Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye.
The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Abpro Holdings, Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Ian Chan |
Contact Details
Address: 68 Cummings Park Drive Woburn, Massachusetts 01801 United States | |
| Phone | 617 225 0808 |
| Website | abpro.com |
Stock Details
| Ticker Symbol | ABP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001893219,CIK_0001670356 |
| Employer ID | 20-1546491 |
Key Executives
| Name | Position |
|---|---|
| Ian Chan | Co-Founder, President, Chief Executive Officer, Secretary and Director |
| Eugene Y. Chan M.D. | Co-Founder, Chairman and Secretary |
| Richard J. Mitrano | Senior Vice President of Finance |
| Christian Zapf | Senior Vice President of Corporate Development and General Counsel |
| Robert J. Markelewicz Jr., M.D. | Chief Medical Officer and Treasurer |